JCR Pharmaceuticals Co., Ltd. (4552) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kyowa Kirin Co., Ltd.

Sumitomo Pharma Co., Ltd.

Tsumura & Co.

Suzuken Co., Ltd.

Nippon Shinyaku Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Santen Pharmaceutical Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is JCR Pharmaceuticals Co., Ltd. ?

The company has declared Negative results for the last 6 consecutive quarters

PRE-TAX PROFIT(Q) At JPY -1,651 MM has Fallen at -99.1%
DEBT-EQUITY RATIO (HY) Highest at 79.8 %
CASH AND EQV(HY) Lowest at JPY 31,264 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 8.09%, its profits have fallen by -199%

Underperformed the market in the last 1 year

The stock has generated a return of 8.09% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 38.30%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is JCR Pharmaceuticals Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

JCR Pharmaceuticals Co., Ltd.

8.09%

0.03

58.31%

Japan Nikkei 225

40.96%

1.35

28.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.94%

EBIT Growth (5y)

-216.09%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

0.45

Net Debt to Equity (avg)

0.53

Sales to Capital Employed (avg)

0.46

Tax Ratio

26.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

20.06%

ROE (avg)

13.01%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.63

EV to EBIT

-14.83

EV to EBITDA

-29.25

EV to Capital Employed

1.41

EV to Sales

3.07

PEG Ratio

Dividend Yield

ROCE (Latest)

-9.51%

ROE (Latest)

-11.65%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

At JPY 21,784 MM has Grown at 22.83%

NET PROFIT(HY)

Higher at JPY 1,564.9 MM

RAW MATERIAL COST(Y)

Fallen by -2.78% (YoY

-18What is not working for the Company

PRE-TAX PROFIT(Q)

At JPY -1,651 MM has Fallen at -99.1%

DEBT-EQUITY RATIO (HY)

Highest at 79.8 %

CASH AND EQV(HY)

Lowest at JPY 31,264 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.46 times

INTEREST(Q)

Highest at JPY 151 MM

Here's what is working for JCR Pharmaceuticals Co., Ltd.

Net Profit

At JPY 1,564.9 MM has Grown at 229.01%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

At JPY 21,784 MM has Grown at 22.83%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Net Profit

Higher at JPY 1,564.9 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Raw Material Cost

Fallen by -2.78% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for JCR Pharmaceuticals Co., Ltd.

Pre-Tax Profit

At JPY -1,651 MM has Fallen at -99.1%

over average net sales of the previous four periods of JPY -829.25 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Interest

At JPY 151 MM has Grown at 93.59%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio

Highest at 79.8 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest

Highest at JPY 151 MM

in the last five periods and Increased by 93.59% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 31,264 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 0.46 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio